Introduction {#S0001}
============

Erectile dysfunction (ED) is associated with increased vascular risk of coronary heart disease and stroke \[[@CIT0001]\]. Increased prevalence rates of ED have been reported in patients with vascular disorders such as myocardial infarction and stroke \[[@CIT0002]\]. Men with ED have a two-fold increased risk for acute myocardial infarction \[[@CIT0003]\]. Because ED is a marker of subclinical coronary artery disease (CAD), many ED patients carry a risk of acute coronary syndrome (ACS). Although the association between cardiovascular risk factors and ED is well established, the predictive role of ED for future cardiovascular events in CAD patients who present with ACS is not known clearly.

Asymmetrical dimethylarginine (ADMA) has recently aroused interest as an endogenous competitive inhibitor of nitric oxide synthases and an independent marker for cardiovascular disease \[[@CIT0004]\]. Generated ADMA is dependent on the extent of arginine methylation in proteins and in the rates of protein turnover and it is extensively metabolized by dimethylarginine dimethylaminohydrolase \[[@CIT0005]\]. It has the potential to produce considerable biological effects, particularly in the endothelial system. Over the last years, several studies have suggested that plasma concentrations of ADMA provide a marker of risk for endothelial dysfunction \[[@CIT0006]\]. Asymmetrical dimethylarginine levels are significantly elevated in men who have early stage coronary atherosclerosis and ED \[[@CIT0007]\]. Assessment of ADMA might aid cardiovascular risk assessment. We investigated whether ADMA has a predictive role for major adverse cardiovascular events (MACE) in CAD patients who presented with ACS. The secondary aim of this study was to investigate whether severity of ED predicts MACE in these patients.

Material and methods {#S0002}
====================

A total of 121 men who presented with ACS and underwent coronary angiography were prospectively enrolled between January 2007 and July 2007 for this study. Thirty-one patients refused participation or returned the International Index of Erectile Function-6 (IIEF-6) questionnaire incomplete. After evaluation of exclusion criteria (heart failure, end stage renal failure, severe valvular heart disease, concomitant chronic severe disease), 90 patients were enrolled into the ongoing study. In 20 patients laboratory values for ADMA were missing and 13 patients' follow-up data of MACE were not available. Asymmetrical dimethylarginine analysis was performed for the remaining 57 patients. For analysis of ED severity, 19 patients' follow-up data of MACE were not available. The remaining 71 subjects with complete baseline and follow-up data were included in the analysis.

Inclusion criteria for ACS were: chest pain consistent with myocardial ischaemia, elevation of troponin-I or creatine kinase above upper limit of normal, and one of the following findings: electrocardiographic evidence of ischaemia, or wall motion abnormality. At the time of inclusion, demographic data, clinical characteristics and current medications were recorded. All patients were evaluated with physical examination and underwent laboratory tests, including lipid profile and fasting glucose. Risk factors were defined as follows: hypertension as blood pressure \> 140/90 mm Hg or taking antihypertensive drugs; hypercholesterolaemia as total cholesterol level \> 190 mg/dl and LDL cholesterol level \> 130 mg/dl; diabetes as fasting glucose level \> 125 mg/dl or taking antidiabetic drugs. The study protocol was approved by the Local Ethics Committee and all patients gave informed consent.

Assessment of erectile dysfunction {#S20007}
----------------------------------

Erectile dysfunction was assessed by the IIEF-6 score \[[@CIT0008]\]. All men were asked to complete the IIEF questionnaire. Erectile function is addressed by 6 questions. Each question is scored 0 to 5. Erectile dysfunction is defined as value \< 26. The severity of ED was classified into 5 categories: no ED (IIEF score 26 to 30), mild (IIEF score 22 to 25), mild to moderate (IIEF score 17 to 21), moderate (IIEF score 11 to 16), and severe (IIEF score \< 10) \[[@CIT0008]\].

Assessment of coronary artery involvement {#S20008}
-----------------------------------------

Coronary angiography was carried out in all patients by the Judkins standard technique. Significant angiographic narrowing was defined as \> 50% diameter stenosis. Coronary artery disease was scored with 1-2-3 vessel disease. Our study included cases with ACS, and because of acute total occlusion, previously modified Gensini score was used for coronary artery involvement \[[@CIT0009]\].

Laboratory investigations {#S20009}
-------------------------

After an overnight fast, venous blood was collected and serum separated and stored at −70°C until batch analysis. All blood samples were taken within 1 week of diagnosis of ACS and before coronary angiography. Blood levels of blood glucose, total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides were measured by standard laboratory methods. ADMA was analysed by the ELISA method (ADMA direct ELISA, Immundiagnostik AG, Bensheim, Germany) according to the manufacturer\'s guidelines.

Study end points and follow-up {#S20010}
------------------------------

The study end point was the occurrence of a first MACE consisting of reinfarction, re-hospitalisation, stroke and all cause death. All patients were then prospectively followed by office visit or by telephone contact at 3-month intervals for the occurrence of first MACE. Outcome was evaluated by 2 observers (M. A., A. B.) who were blinded with respect to the patients' baseline clinical and laboratory data.

Statistical analysis {#S20011}
--------------------

Continuous data are presented as medians (min-max values) for both ADMA and IIEF-6 score. Categorical data are given as counts (percentages). Mann-Whitney *U* test was applied for univariate comparison of continuous data and Spearman rank correlation for assessment of associations between continuous variables. ROC analysis was used for ADMA cut-off values. Event-free survival rates until the first cardiovascular adverse event according to ADMA levels (ROC analysis) and IIEF score were calculated using the Kaplan-Meier method and compared by the log rank test. Multivariate Cox proportional hazards analysis was used to assess the independent effect of ADMA and IIEF on the composite end point and to adjust for potential confounders. Continuous variables were included as confounders if these variables were associated with ADMA and IIEF according to Spearman rank correlation coefficients. Categorical variables were entered into the model if they influenced ADMA and IIEF according to univariate analysis. In addition, adjustment for traditional cardiovascular risk factors was performed. Results of the Cox proportional hazards model are presented as hazard ratio and 95% confidence interval (CI) as well as survival curves according to cut-off values of ADMA and IIEF. *P* values \< 0.05 were considered to indicate statistical significance.

According to a retrospective power analysis for ADMA level in patients, when 57 patients and HR = 2.018 are used, power is calculated as 0.275 (α = 0.05). Data were analysed using NCSS 2008 Demo for Windows (NCSS, Kaysville, UT, USA).

Results {#S0003}
=======

Ninety patients were eligible for the study. In 20 patients laboratory values for ADMA were missing and 13 patients' follow-up data of MACE were not available. Asymmetrical dimethylarginine analysis was performed for the remaining 57 patients. For analysis of ED severity, 19 patients' follow-up data of MACE were not available. The remaining 71 subjects with complete baseline and follow-up data were included in the analysis. Follow-up duration was median 10 months (range: 1−13 months).

Asymmetrical dimethylarginine and survival {#S20013}
------------------------------------------

Median ADMA plasma concentration of all patients was 0.50 µmol/l (IQR, 0.06 to 1.41). Factors potentially influencing ADMA concentrations such as the presence of risk factors of atherosclerosis, medication, coronary vessels involvement, and revascularisation were not significantly different ([Table I](#T0001){ref-type="table"}). Asymmetrical dimethylarginine was elevated in the patients without diabetes mellitus and the group without antidiabetic therapy and correlated negatively with age and Gensini score ([Table II](#T0002){ref-type="table"}). During follow-up, 5.3% reinfarction, 12.3% hospitalisation, and 8.8% all-cause death occurred in 57 patients, and the revascularisation rate was 63.2%. When the cut-off value of ADMA 0.32 µmol/l was accepted according to ROC analysis, \> 0.32 µmol/l yielded a sensitivity of 70% and a specificity of 28% for detecting CAD which presented ACS. Thus, according to ADMA cut-off value 0.32 µmol/l, 57 subjects were divided into 2 groups. Twenty-nine percent MACE in the patients who had ADMA levels \< 0.32 µmol/l and 17.5% MACE in other patients occurred during the follow-up period (*p* = 0.236, χ^2^ = 1.405, log rank test). The patients who had ADMA levels ≥ 0.32 µmol/l had no significantly increased hazard ratio for cardiovascular events compared with patients who had ADMA levels \< 0.32 µmol/l after adjustment for possible confounders (2.018 \[95% CI 0.615--6.626\], *p* = 0.247 ([Table III](#T0003){ref-type="table"}).

###### 

Median plasma concentrations (interquartile range) of ADMA and IIEF score grouped according to categorical baseline variables

                                     *N*   ADMA \[µmol/l\]     *P* value   *N*   IIEF (score)   *P* value
  ---------------------------------- ----- ------------------- ----------- ----- -------------- -----------
  **Risk factors**                                                                              
   Hypertension                                                                                 
    Yes                              21    0.44 (0.06--1.30)               26    18 (1--30)     
    No                               36    0.55 (0.09--1.41)   0.155       44    20 (1--30)     0.363
   Diabetes mellitus                                                                            
    Yes                              9     0.16 (0.06--0.84)               15    11 (1--26)     
    No                               48    0.54 (0.09--1.41)   0.001       53    21 (1--30)     0.002
   Hyperlipidaemia                                                                              
    Yes                              6     0.34 (0.08--0.71)               7     26 (15--30)    
    No                               51    0.50 (0.06--1.41)   0.233       63    19 (1--30)     0.116
   Smoking current                                                                              
    Yes                              33    0.55 (0.09--1.41)               41    20 (1--30)     
    No                               24    0.45 (0.06--1.28)   0.070       29    15 (1--30)     0.031
   Smoking former                                                                               
    Yes                              46    0.50 (0.08--1.41)               57    19 (1--30)     
    No                               11    0.47 (0.06--1.28)   0.537       13    20 (1--30)     0.867
  **Medication**                                                                                
   β-Blocker therapy                                                                            
    Yes                              14    0.52 (0.08--1.13)               16    24 (1--30)     
    No                               43    0.47 (0.06--1.41)   0.882       54    18.5 (1--30)   0.187
   ACE inhibitors therapy                                                                       
    Yes                              15    0.49 (0.06--1.30)               17    21 (1--30)     
    No                               42    0.52 (0.08--1.41)   0.906       53    19 (1--30)     0.283
   AT2 receptor blocker therapy                                                                 
    Yes                              5     0.43 (0.08--0.97)               7     22 (1--30)     
    No                               52    0.52 (0.06--1.41)   0.401       63    19 (1--30)     0.549
   Calcium antagonist therapy                                                                   
    Yes                              4     0.78 (0.38--1.13)               4     15.5 (1--28)   
    No                               53    0.49 (0.06--1.41)   0.142       66    19.5 (1--30)   0.470
   Diuretic therapy                                                                             
    Yes                              1     1.30 (1.30--1.30)               1     30 (30--30)    
    No                               56    0.49 (0.06--1.41)   0.070       69    19 (1--30)     0.143
   Statin therapy                                                                               
    Yes                              5     0.58 (0.28--1.13)               7     26 (9--30)     
    No                               52    0.49 (0.06--1.41)   0.671       63    19 (1--30)     0.242
   Acetylsalicylic acid therapy                                                                 
    Yes                              18    0.46 (0.06--1.41)               20    21.5 (1--30)   
    No                               39    0.54 (0.12--1.28)   0.589       50    19 (1--30)     0.293
   Clopidogrel therapy                                                                          
    Yes                              5     0.50 (0.28--1.13)               6     20.5 (1--30)   
    No                               52    0.49 (0.06--1.41)   0.838       64    19 (1--30)     0.976
   Anticoagulant therapy                                                                        
    Yes                              1     0.49 (0.49--0.49)               1     24 (24--24)    
    No                               56    0.50 (0.06--1.41)   0.982       69    19 (1--30)     0.686
   Oral antidiabetic therapy                                                                    
    Yes                              6     0.06 (0.08--0.84)               9     12 (1--26)     
    No                               51    0.54 (0.06--1.41)   0.017       61    20 (1--30)     0.032
   Insulin therapy                                                                              
    Yes                              3     0.15 (0.06--0.84)               3     1 (1--18)      
    No                               54    0.50 (0.08--1.41)   0.259       67    20 (1--30)     0.058
  **Coronary vessels involvement**                                                              
   One-vessel disease                                                                           
    Yes                              17    0.54 (0.16--1.28)               21    24 (1--30)     
    No                               40    0.47 (0.06--1.41)   0.958       49    18 (1--30)     0.053
   Two-vessel disease                                                                           
    Yes                              18    0.61 (0.18--1.26)               20    18.5 (1--30)   
    No                               39    0.47 (0.06--1.41)   0.066       50    20 (1--30)     0.527
   Three-vessel disease                                                                         
    Yes                              22    0.35 (0.06--1.41)               29    18 (1--30)     
    No                               35    0.55 (0.16--1.28)   0.071       41    20 (1--30)     0.222
   Total occlusion                                                                              
    Yes                              13    0.38 (0.06--1.10)               15    18 (1--30)     
    No                               44    0.54 (0.09--1.41)   0.068       55    20 (1--30)     0.499
   Revascularisation                                                                            
    Yes                              36    0.43 (0.06--1.30)               45    21 (1--30)     
    No                               21    0.54 (0.16--1.41)   0.317       25    15 (1--30)     0.056

###### 

Baseline characteristics and Spearman correlation coefficients (*p* value) for ADMA and IIEF score and continuous variables of acute coronary syndrome

                                        Median (min-max)      ADMA (R)   *P* value   Median (min-max)    IIEF score (R)   *P* value
  ------------------------------------- --------------------- ---------- ----------- ------------------- ---------------- -----------
  **Age \[year\]**                      58 (35--79)           −0.301     0.02        58 (35--79)         −0.635           0.000
  **Body mass index \[kg/m**^2^**\]**   26.22 (18.8--42.59)   −0.137     0.31        26.2 (18.8--42.6)   0.139            0.251
  **Cholesterol \[mg/dl\]**             182 (86--278)         −0.279     0.47        177.5 (86--326)     0.340            0.291
  **Triglycerides \[mg/dl\]**           128 (50--410)         0.007      0.96        132 (40--410)       0.071            0.573
  **LDL cholesterol \[mg/dl\]**         113 (29--214)         −0.282     0.04        112 (29--320)       0.056            0.658
  **HDL cholesterol \[mg/dl\]**         36 (22--50)           −0.342     0.01        35 (22--50)         0.202            0.116
  **Ejection fraction \[%\]**           50 (57--30.74)        0.102      0.48        57 (30--74)         0.080            0.541
  **Gensini score**                     33 (7--117)           −0.291     0.03        39 (7--122)         −0.309           0.009
  **IIEF score**                        21 (1--30)            0.247      0.06        19 (1--30)          --               --
  **ADMA \[µmol/l\]**                   0.50 (0.06--1.41)     --         --                                               

###### 

Cox regression analysis assessing the multivariate hazard ratio for ADMA

                            Hazard ratio (95% CI)   *P* value
  ------------------------- ----------------------- -----------
  **ADMA \< 0.32 µmol/l**   1                       
  **ADMA ≥ 0.32 µmol/l**    2.018 (0.615--6.626)    0.247

Cut-off value 0.32 Umol/l according to ROC analysis (sensitivity 70%, specificity 27%). Multivariate model: adjustment for age, total cholesterol, LDL cholesterol, fasting blood glucose and Gensini score

Severity of erectile dysfunction and survival {#S20014}
---------------------------------------------

During follow-up 20 (28.5%) MACE occurred in 71 patients including 7.1% reinfarction, 14.3% hospitalisation, and 7.1% all-cause death, and the revascularisation rate was 64.3%. When patients were divided into 5 groups according to severity of ED, no ED had no significantly increased hazard ratio for cardiovascular events compared with mild, mild to moderate, moderate ED, and severe ED after adjustment for possible confounders (0.259 \[95% CI 0.041--1.610\], *p* = 0.147; 0.605 \[95% CI 0.095--3.843\], *p* = 0.594; 0.980 \[95% CI 0.233--4.121\], *p* = 0.978; 0.473 \[95% CI 0.052--1.345\], *p* = 0.508, respectively). (According to multivariate Cox regression analysis) ([Table IV](#T0004){ref-type="table"}).

###### 

Cox regression analysis assessing the multivariate hazard ratio for IIEF scoring

                                                 Hazard ratio (95% CI)   *P* value
  ---------------------------------------------- ----------------------- -----------
  **No ED (IIEF score 26 to 30)**                1                       
  **Mild ED(IIEF score 22 to 25)**               0.259 (0.041--1.610)    0.147
  **Mild to moderate ED(IIEF score 17 to 21)**   0.605 (0.095--3.843)    0.594
  **Moderate ED(IIEF score 11 to 16)**           0.980 (0.233--4.121)    0.978
  **Severe ED(IIEF score 1 to 10)**              0.473 (0.052--1.345)    0.508

Multivariate model: adjustment for age, diabetes mellitus, current smoking, oral antidiabetic therapy

Discussion {#S0004}
==========

Our findings showed that serum ADMA concentrations and severity of ED did not predict major cardiovascular events after adjustment of confounder factors in patients with CAD who presented with ACS in this study population. No difference, in terms of serum ADMA and severity of ED, was seen between the MACE group and the group without MACE.

Over the last decade, several studies have shown that circulating concentrations of ADMA can be influenced by many factors. Treatment with rosuvastatin \[[@CIT0010]\], rosiglitazone, metformin, ACE inhibitors and AT-2 receptor blockers have decreased ADMA concentrations in humans \[[@CIT0011], [@CIT0012]\]. In addition, ADMA is a well characterized marker that has been associated with many traditional risk factors and vascular disorders, as demonstrated for hypertension \[[@CIT0013]\], hyperhomocysteinaemia \[[@CIT0014]\], peripheral artery disease \[[@CIT0015]\], and stroke \[[@CIT0016]\]. Barylski *et al*. \[[@CIT0017]\] showed that renal failure may be related to impaired endothelial function. Vallance *et al*. \[[@CIT0018]\] demonstrated that accumulation of endogenous ADMA, as an indicator of endothelial dysfunction, is associated with chronic renal failure.

In our study, factors potentially influencing ADMA concentrations and prognosis after ACS were not significantly different, such as the presence of risk factors of atherosclerosis, medication, coronary vessels involvement, revascularisation, and valve disease. In our study, ADMA serum concentrations were low in diabetic patients. This paradoxical finding could in part be explained by administration of oral antidiabetic therapy in half of the diabetic population. Metformin and thiazolidinediones reduce ADMA levels \[[@CIT0019], [@CIT0020]\]. Furthermore, our results indicate that hypertension, hyperlipidaemia, smoking, medications including β-blocker therapy, ACE inhibitors and AT-2 blocker therapy, statins, diuretics, calcium channel blockers and antiaggregant therapy did not influence serum ADMA concentrations. Asymmetrical dimethylarginine concentrations were not different in patients on statin therapy or antihypertensive therapy in the present cohort.

Since the demonstration that concentration of ADMA acts as a marker of endothelial dysfunction, circulating levels of ADMA have been related to the presence of coronary artery disease \[[@CIT0021]\] and the occurrence of acute coronary syndrome \[[@CIT0022]\]. Schnabel *et al*. \[[@CIT0023]\] showed that circulating ADMA adds independent prognostic information in patients with CAD. Valkonen *et al*. \[[@CIT0021]\] demonstrated that high concentrations of ADMA in serum are associated with an increased risk of acute coronary events among non-smoking middle-aged men, especially in men with previous coronary heart disease. A recent study in patients with acute MI reported that the baseline ADMA level has prognostic value for mortality after acute myocardial infarction \[[@CIT0024]\]. Asymmetrical dimethylarginine was not associated with future cardiovascular events in the present study. This could be explained by the fact that our study sample was small and all male. Meinitzer *et al*. \[[@CIT0025]\] demonstrated that ADMA concentrations predict all-cause and cardiovascular mortality in individuals with stable and acute CAD. A difference of their study was inclusion of patients with stable CAD.

Our trial is the first study in the literature to investigate whether severity of ED predicts major cardiovascular events in patients with coronary artery disease with ACS. Vascular disease and ED have similar pathogenic involvement of the nitric oxide pathway leading to impairment of endothelium dependent vasodilatation and structural vascular abnormalities \[[@CIT0026], [@CIT0027]\]. Montorsi *et al*. identified ED as a predictor of acute coronary syndromes \[[@CIT0028]\]. They showed that ED occurred before CAD symptoms in 67% of patients with ED. Thus, they reinforced that ED might predict the presence of subclinical vulnerable plaque. Ponholzer *et al*. \[[@CIT0029]\] showed that moderate-to-severe ED was calculated to increase the 10-year relative risk of developing CAD by 65% and stroke by 43%. Another trial showed that ED significantly predicted cardiac events \[[@CIT0030]\]. Montorsi *et al*. \[[@CIT0009]\] found that severe ED was more frequent in patients with multi-vessel as compared to single vessel disease. Thus, severe ED should raise questions about prognosis in patients with CAD. We found that severity of ED did not predict future cardiovascular events in patients with ACS. Recently published data have demonstrated that ED is a powerful predictor of cardiovascular morbidity and mortality in diabetic patients with silent CAD \[[@CIT0031]\]. Large prospective studies are necessary to evaluate whether ED predicts cardiovascular events in patients with ACS.

Our study is limited by the relatively small sample size. The relatively small number of male patients could be the reason why ADMA and severity of ED are not predictive in our study. Bae *et al*. \[[@CIT0032]\] found a significant decrease in ADMA levels after 2 weeks of medical therapy for ACS. Because of this we took blood samples within 1 week after diagnosis of ACS before coronary angiography. Although the majority of published methods for determination of plasma concentrations of ADMA are based on high performance liquid chromatography (HPLC), we determined ADMA by a recently atracted ELISA method that is suitable for the determination of ADMA in large sample series to be analysed more quickly than HPLC \[[@CIT0033]\]. It may be a limitation of our study. Additionally, only male patients participated in the study, which is a further limitation. A recent study found that a 0.15 µmol/l increase in baseline ADMA levels was associated with approximately 30% increase in incident cardiovascular risk in 880 healthy women \[[@CIT0034]\]. However, whether ADMA concentrations are different in males and females with ACS is not known. After performing power analysis in our study we considered that large prospective studies, also including female patients, are necessary to evaluate whether ADMA predicts cardiovascular events in patients with ACS.

In conclusion, the results of this prospective study suggest that ADMA and severity of ED did not predict future cardiovascular events in this patient group. Larger prospective studies with longer follow-up are necessary to evaluate whether ADMA and ED predict MACE in patients with ACS.
